These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 23270554)

  • 1. Cardioprotection techniques: preconditioning, postconditioning and remote conditioning (basic science).
    Hausenloy DJ
    Curr Pharm Des; 2013; 19(25):4544-63. PubMed ID: 23270554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preconditioning and postconditioning: underlying mechanisms and clinical application.
    Hausenloy DJ; Yellon DM
    Atherosclerosis; 2009 Jun; 204(2):334-41. PubMed ID: 19081095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
    Ferdinandy P; Schulz R; Baxter GF
    Pharmacol Rev; 2007 Dec; 59(4):418-58. PubMed ID: 18048761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.
    Penna C; Andreadou I; Aragno M; Beauloye C; Bertrand L; Lazou A; Falcão-Pires I; Bell R; Zuurbier CJ; Pagliaro P; Hausenloy DJ
    Br J Pharmacol; 2020 Dec; 177(23):5312-5335. PubMed ID: 31985828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.
    Ferdinandy P; Andreadou I; Baxter GF; Bøtker HE; Davidson SM; Dobrev D; Gersh BJ; Heusch G; Lecour S; Ruiz-Meana M; Zuurbier CJ; Hausenloy DJ; Schulz R
    Pharmacol Rev; 2023 Jan; 75(1):159-216. PubMed ID: 36753049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury.
    Sivaraman V; Yellon DM
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):83-96. PubMed ID: 24038018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection.
    Caricati-Neto A; Errante PR; Menezes-Rodrigues FS
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remote ischemia conditioning-an endogenous cardioprotective strategy from outside the heart.
    Xiong J; Liao X; Xue FS; Yuan YJ; Wang Q; Liu JH
    Chin Med J (Engl); 2011 Jul; 124(14):2209-15. PubMed ID: 21933628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous Cardioprotective Agents: Role in Pre and Postconditioning.
    Penna C; Granata R; Tocchetti CG; Gallo MP; Alloatti G; Pagliaro P
    Curr Drug Targets; 2015; 16(8):843-67. PubMed ID: 25751010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Platelets in Ischemic Conditioning.
    Alpuche J; Quírino L; Sánchez-Vega JT; Yap J; Pérez-Campos E; Cabrera-Fuentes HA
    Cond Med; 2018 Oct; 1(6):313-318. PubMed ID: 30556056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protecting the heart from ischemia: an update on ischemic and pharmacologic conditioning.
    Gerczuk PZ; Kloner RA
    Hosp Pract (1995); 2011 Aug; 39(3):35-43. PubMed ID: 21881390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notch signaling activation contributes to cardioprotection provided by ischemic preconditioning and postconditioning.
    Zhou XL; Wan L; Xu QR; Zhao Y; Liu JC
    J Transl Med; 2013 Oct; 11():251. PubMed ID: 24098939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent.
    Hausenloy DJ; Boston-Griffiths EA; Yellon DM
    Br J Pharmacol; 2012 Mar; 165(5):1235-45. PubMed ID: 21955136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remote ischemic conditioning: a clinical trial's update.
    Candilio L; Hausenloy DJ; Yellon DM
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):304-12. PubMed ID: 21821533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protecting the heart from ischemia/reperfusion injury: an update on remote ischemic preconditioning and postconditioning.
    Donato M; Evelson P; Gelpi RJ
    Curr Opin Cardiol; 2017 Nov; 32(6):784-790. PubMed ID: 28902715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotection from ischemia/reperfusion injury: basic and translational research.
    Minamino T
    Circ J; 2012; 76(5):1074-82. PubMed ID: 22504127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is oxytocin a therapeutic factor for ischemic heart disease?
    Alizadeh AM; Mirzabeglo P
    Peptides; 2013 Jul; 45():66-72. PubMed ID: 23659864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning.
    Heusch G
    Circ Res; 2015 Feb; 116(4):674-99. PubMed ID: 25677517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Realizing the clinical potential of ischemic preconditioning and postconditioning.
    Yellon DM; Hausenloy DJ
    Nat Clin Pract Cardiovasc Med; 2005 Nov; 2(11):568-75. PubMed ID: 16258568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 2J3/epoxyeicosatrienoic acids mediate the cardioprotection induced by ischaemic post-conditioning, but not preconditioning, in the rat.
    Yu GG; Zeng XJ; Wang HX; Lu LQ; Zheng SP; Ma LQ; Chang J; Wang J; Zhang DM; Du FH; Zhang LK
    Clin Exp Pharmacol Physiol; 2011 Jan; 38(1):63-70. PubMed ID: 21105892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.